Amrita Therapeutics is in the vanguard of biotechnology companies translating microbiomic technologies into practical tools to benefit patients, with a diverse range of programs at the discovery stage and late preclinical stages.
Our lead Drug Candidate AT-01C is a p53 tumor suppressor peptide derived from Mycobacterium Tuberculosis (M. bovis) Protein MPT63, also known as ATP-01.
AT-01C shows tumor-shrinking, anti-metastasis & anti-inflammatory activity in solid tumors including colorectal, bladder and liver cancer, binding to SMAR1 – Scaffold Matrix Attachment Region Binding Protein 1 – for down-regulation of oncogenes with little or no toxicity to healthy tissues.
In parallel to clinical development for AT-01C, Amrita Therapeutics is focusing on the 'master-regulator' SMAR1 biomarker as a companion diagnostic test to identify patients most likely to benefit from AT-01C therapy.
Amrita Therapeutics was launched at the height of the global financial crisis at Vibrant Gujarat in early 2009 with seed funding from the Gujrat Venture Finance Limited (GVFL), and has received international recognition for its innovative research platform.
Amrita Therapeutics proprietary science platform leverages our increasing understanding of the important role of the microbiome in human health, ushering in a new golden age of drug development.